McKesson Corporation (NYSE:MCK) is one of the best performing S&P 500 stocks in the last five years, with BofA recently reaffirming its ‘Buy’ rating on the company following a strong third quarter performance. BofA raised its price target from $950 to $970, citing revenue and EPS exceeding street expectations. McKesson raised its fiscal 2026 adjusted EPS forecast to $38.80-$39.20. The company reported third quarter revenue of $106.16 billion and adjusted EPS of $9.34, with U.S. pharmaceutical segment sales rising 9% to $88.30 billion. McKesson offers pharmaceutical distribution, specialty drug solutions, and medical-surgical supplies. While MCK shows investment potential, certain AI stocks may offer greater upside with lower downside risk.

Read more at Yahoo Finance: BofA Remains Bullish on McKesson (MCK) Following Strong Third Quarter Performance